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Abstract: In recent years, novel classes of noncoding RNAs 
(ncRNAs) have been discovered, which are implicated in diverse 
functional and regulatory activities. Growing evidence indicates that 
deregulated ncRNAs play crucial roles in the onset and progression of 
cancer, including small-cell lung cancer. In this review, we highlight 
nearly all of the findings regarding the roles and the possible mecha-
nisms of ncRNAs as oncogenes or tumor suppressors in small-cell 
lung cancer. Furthermore, we discuss the possible role of ncRNAs as 
diagnostic biomarkers, their significant contribution to the prognosis, 
and their functions in regulating the response to therapy.
Key Words: Non-coding RNA, Small cell lung cancer.
(J Thorac Oncol. 2015;10: 28–37)
Lung cancer is the most common cancer worldwide, inflict-ing over 1,090,000 men and 515,000 women annually. In 
addition, it is the leading cause of cancer mortality, responsi-
ble for 18.2% of all cancer deaths (World Health Organization. 
Cancer. 2013; http://globocan.iarc.fr).1 Small-cell lung cancer 
(SCLC), accounting for approximately 15% of all lung can-
cers, is the most aggressive lung cancer type, with a 2-year 
survival rate of less than 5%.2 Despite advances in chemo-
therapy, radiotherapy and our understanding of the molecular 
mechanisms of SCLC, most SCLC patients still succumb to 
the disease within 1 year.3 This poor prognosis is largely due 
to the late stage at diagnosis and the lack of effective thera-
peutic regimens.4,5 Thus, considerable effort is warranted to 
improve early diagnosis and targeted therapies for SCLC.
Noncoding RNAs (ncRNAs) are typically classified into 
two groups according to their size: small ncRNAs of less than 
200 nucleotides (nt), which include microRNAs (miRNAs), 
Piwi-interacting RNAs and small nucleolar RNAs, and long 
ncRNAs (lncRNAs, >200 nt).6,7 In recent years, it has become 
increasingly apparent that ncRNAs are of crucial functional 
importance for both normal development and physiology and 
for disease.8 They participate in target gene silencing, as well 
as transcriptional, post-transcriptional, and epigenetic pro-
cesses. The latter events include chromatin remodeling and 
nuclear reorganization, which, in turn, involves the formation 
of silent compartments and the fine-tuning of gene recruitment 
into these compartments.7 Recent evidence has implicated 
several ncRNAs in SCLC tumorigenesis and tumor progres-
sion, which has opened the door to ncRNA-based molecular 
diagnosis and therapy of SCLC.
In the present review, we summarize the primary find-
ings regarding the biogenesis, regulation, and function of 
ncRNAs in SCLC, and discuss their diagnostic and prognostic 
value and potential clinical utility.
miRNAs iN sCLC
Biogenesis and modification of miRNAs in sCLC
miRNAs, the most extensively studied ncRNAs, are 
small ncRNAs of approximately 22 nt with a role in post-
transcriptional gene silencing.9 They are transcribed as inde-
pendent genes into 1 to 3 kb long precursors (pri-miRNAs) 
by RNA polymerase II or III. The pri-miRNAs undergo pro-
cessing by Drosha-DGCR8 (microprocessor), giving rise to 
precursor miRNAs (pre-miRNAs) that are exported to the 
cytoplasm by the nuclear transport factor exportin-5 (XPO5). 
The pre-miRNAs are then cleaved by Dicer to mature imper-
fect RNA duplexes. Then the passenger strand is degraded, 
and the other guide stranded mature miRNA associates with 
Argonaute (AGO) proteins to form a miRNA-induced silenc-
ing complex (RISC), which leads to mRNA degradation or 
translational inhibition by binding to the 3′-untranslated region 
(3′-UTR) of target mRNA.10,11 Alternatively, miRNAs can also 
be derived from the introns of protein-coding genes through 
splicing, after which they are cleaved into lariats by Dicer and 
enter the canonical pathway.12,13 Some miRNAs are released 
as cell-free miRNAs from the cytoplasm into the extracellu-
lar environment. This release occurs through the packaging 
of miRNAs into various membrane-bound vesicles, such as 
exosomes, microvesicles, and apoptotic bodies.14–16
Aberrant miRNAs expression has been reported in 
many cancers including SCLC and non–small-cell lung cancer 
(NSCLC). Genetic and epigenetic alterations are implicated 
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in the aberrant expression of miRNAs. Nearly 50% of miR-
NAs are located in deleted regions, amplified regions, and 
breakpoint regions involved in human cancers.17 The miR-
17–92 family resides in 13q31.3, and the chromosome frag-
ment frequently amplified in SCLC.18,19 Defects in the miRNA 
biogenesis machinery may also be closely related to aber-
rant miRNAs expression. Lin-28 inhibits the biogenesis of 
let-7 miRNAs by blocking both Drosha- and Dicer-mediated 
cleavage and accelerating the decay of let-7 pre-miRNAs.20–25 
In addition, the SNP in pre-miRNA is another factor that 
affects the expression of mature miRNAs and miRNA tar-
get genes. miR-196a2 and miR-146a are modified in this 
manner.26,27 Besides, the aberrant miRNAs expression could 
also be induced by changes in the miRNA promoter. DNA 
methylation of the promoter occurs for miR-34b/c and miR-
886-3p.28,29 miR-375 is activated through the binding of ASH1 
to the three E-box elements in the promoter.30,31
Overall, the complex process of miRNA biogenesis has 
nearly been fully understood, and the modification mechanisms 
of miRNA in SCLC have also been extensively investigated in 
recent years. Considering the increasing interest in translating 
miRNAs into the cancer clinic, clearly elucidating the biogen-
esis and modification of miRNA is a significant prerequisite 
not only for fully understanding the functions of miRNAs in 
SCLC but also to integrate miRNA into clinical applications.
miRNAs Regulate sCLC Cell Viability
Previous studies demonstrated that miRNAs are always 
involved in the tumorigenesis of SCLC by regulating oncogenes 
and tumor suppressor genes that play crucial roles in cell prolif-
eration, apoptosis, migration, and invasion (see Table 1).
miRNAs Function as Oncogenes in sCLC
The members of the miR-17–92 cluster (miR-17, miR-
18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1), which 
resides in the 13q31.3, are the first miRNAs to be recog-
nized as oncogenes. The miR-17–92 cluster is significantly 
overexpressed in SCLC, which enhances cell proliferation 
and inhibits apoptosis.18,19 Ebi et al.32 found that miR-17–92 
TABLE 1.  ncRNAs Regulate Cell Viability in SCLC
ncRNA
Direction of 
Expression in 
SCLC Material Function Effector Ref.
Oncogenic miRNAs
miR-17–92 cluster Up Lung cancer cell lines, 
immortalized lung epithelial 
cell lines, lung cancer tissues, 
and normal lung tissues
Enhances cell proliferation, 
inhibits apoptosis and protects 
against DNA damage.
miR-20a targets E2F1 and 
downregulates the cyclin-
dependent kinase inhibitor p21 
and the pro-apoptotic protein 
Bim, but not the PP2A catalytic 
subunit (PP2Ac).
18, 19, 32
miR-93, miR-98,  
miR-197
Up Lung cancer cell lines and FFPE 
lung tumor tissue specimens
Inhibit tumor suppressor gene 
FUS1 expression.
FUS1 33
miR-375 Up Human lung cancer cell lines and 
specimens and mouse SCLC- 
like model tumors
Induces NE differentiation. ASH1-miR-375-YAP1 pathway 30, 31
Oncogenic lncRNA
HOTAIR Up SCLC cell lines and surgical 
SCLC samples
Promotes proliferation and 
invasion
NS 34
Tumor suppressive miRNAs
let-7 family Down A SCLC cell line Suppresses cell proliferation by 
inducing cell cycle arrest at the 
G1 phase
Repressed by Lin-28 and targets 
CDC25
24
miR-34b/c Down Resected lung cancer tumor 
specimens, malignant pleural 
effusions from SCLC patients, 
and lung cancer cell lines
Inhibits cell growth, migration, 
and invasion.
NS 28
miR-126 Down SCLC cell lines and primary 
tumors
Inhibits cell proliferation by 
arresting the cells in the G1 
phase.
SLC7A5 3, 35
miR-27a Down SCLC cell lines Decreases cell proliferation, 
self renewal, and promotes 
differentiation.
NS 36
miR-886-3p Down SCLC cell lines and FFPE 
specimens
Inhibits cell proliferation, 
migration, invasion, tumor 
growth, and lung metastasis.
PLK1 and TGF-β1 29
miR-335 Down SCLC cell lines and mouse SCLC 
skeletal metastases model
Reduces cell migration, invasion, 
proliferation, and metastasis.
IGF-1R and RANKL pathways 37
FFPE, formalin-fixed paraffin-embedded; ncRNAs, noncoding RNAs; NE, neuroendocrine; NS, not specified; SCLC, small cell lung carcinoma.
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overexpression counterbalances the generation of DNA damage 
in RB-inactivated SCLC cells, thus reducing excessive DNA 
damage to a tolerable level and leading to genetic instability.
MiR-93, miR-98, and miR-197, which target the tumor 
suppressor gene FUS1/TUSC2, are additional examples of 
miRNAs with oncogenic properties in SCLC. As early as 
1982, deletions in the short arm of chromosome 3 (3p) were 
identified and characterized in SCLC cell lines and cultures. 
FUS1/TUSC2, located on 3p21.3, was reduced in or com-
pletely deleted from 82% and 100% of NSCLC and SCLC 
cell lines, respectively. In contrast to FUS1/TUSC2, miR-93 
and miR-98 are expressed at higher levels in SCLC cell lines 
than in NSCLC cell lines and immortalized human bronchial 
epithelial cell (HBEC) line, whereas miR-197 is expressed 
at higher levels in SCLC and in NSCLC cell lines than in 
the HBEC line. In addition, miR-93, miR-98, and miR-197 
function as oncomirs by directly inhibiting the expression of 
FUS1/TUSC2. Furthermore, elevated miR-93 and miR-197 
expression correlates with reduced Fus1/TUSC2 expression 
in NSCLC tumor specimens.33,38,39
The pro-tumor mechanism of another miRNA, miR-
375, in SCLC is also relatively well identified. Most SCLC 
cell lines display overexpression of miR-375, whereas miR-
375 is only weakly expressed in the lung adenocarcinoma 
(AD) and lung squamous cell carcinoma (SQ) cell lines. MiR-
375, a direct transcriptional target for achaete-scute complex 
homolog 1 (ASH1/ASCL1), is upregulated by the direct inter-
action between ASH1 and the E-box elements in the miR-375 
promoter. In addition, miR-375 mediates signals required for 
the ASH1-mediated induction of neuroendocrine features in 
lung cancers, the majority of which are SCLCs. Furthermore, 
miR-375 is highly expressed in the cell lines generated from 
mouse SCLC-like tumors, and its expression correlates with 
ASH1/ASCL1.31 The transcriptional coactivator YAP1, which 
negatively correlates with miR-375, has been found to be a 
direct target of miR-375 and showed growth inhibitory activ-
ity in SCLC cell lines. Taken together, the downregulation of 
YAP1 by ASH-1-transactivated miR-375 promotes the growth 
of SCLC cells, and the ASH1-miR-375-YAP1 pathway plays a 
key role in lung cancers exhibiting neuroendocrine features.30
miRNAs Function as Tumor suppressors in sCLC
The let-7 family is a cluster of miRNAs whose genes 
map to different chromosomal regions that are frequently 
deleted in lung cancer.17 The downregulation of let-7 in SCLC 
is induced by the RNA-binding protein Lin-28, which blocks 
both Drosha- and Dicer-mediated cleavage and promotes cell 
cycle progression and cell proliferation.24 Microarray analysis 
identified many cell cycle-associated genes that are directly or 
indirectly repressed by let-7, and further reporter assays vali-
dated that cell cycle regulators CDK6 and CDC25A are direct 
targets of let-7.40 In SCLC, it was found that let-7 knockdown 
results in the upregulation of CDC25A, which is necessary 
for the progression from the G1 phase to the S phase of the 
cell cycle. Taken together, the reduced expression of let-7 in 
SCLC, induced by Lin-28, enhances cell proliferation by pro-
moting cell cycle progression at the G1 phase through upregu-
lation of CDC25A.
Members of the miR-34 family, another important 
group of miRNAs, function as tumor suppressors and are 
down-expressed in a variety of cancers, including SCLC.41–43 
Methylation of miR-34 family has been detected in SCLC cell 
lines and clinical specimens and is responsible for the reduced 
expression of miR-34 family in SCLC. Furthermore, the 
frequency of miR-34b/c methylation is significantly higher 
in SCLC than in NSCLC. The transfection of miR-34b/c 
into SCLC cell lines resulted in significant inhibition of cell 
growth, migration, and invasion compared with control treat-
ment, which indicates that the aberrant methylation of miR-
34b/c plays an important role in the pathogenesis of SCLC.28 
Although miR-34a is known to play a key role in p53-medi-
ated apoptosis in NSCLC, thereby affecting NSCLC cell sur-
vival,44 Lee et al. showed that expression of miR-34 family 
members is not related to P53 protein expression in SCLC 
tumors. In addition, neither increased nor decreased expres-
sion of miR-34a in SCLCs affects cell viability, malignant 
behavior, or the endogenous expression of the miR-34a target 
genes cMET and Axl in NSCLC cell lines.43 These findings 
further validate the specificity of miRNA function in the con-
text of different lung cancer subtypes.
Additional miRNAs have been showed to act as tumor 
suppressors in SCLC. Microarray and real-time reverse tran-
scription polymerase chain reaction (RT-PCR) analyses vali-
dated that miR-126 expression is uniformly decreased in 
SCLC cell lines and primary tumors.35 Transfection of the 
SCLC cell lines H69 and HTB192 with miR-126 inhibited 
cell proliferation by arresting the cells in the G1 phase. Short 
interfering RNA-mediated suppression of SLC7A5, a direct 
target of mir-126 in SCLC, causes the same effects on H69 
cells, suggesting that miR-126 performs tumor suppressor 
function that is mediated by the downregulation of its target 
SLC7A5.35 Miao et al.36 showed that miR-27a is consistently 
downregulated in sphere-forming cells of all three SCLC cell 
lines (H446, H209, and H69), and that antagonizing miR-27a 
using an inhibitor in parental cells enhances the proliferation, 
self renewal, and proportion of undifferentiated cells in vitro.
Recent evidence suggests that miR-886-3p, regulated by 
DNA hypermethylation of its promoter, is another important 
tumor suppressor in SCLC.29 MiR-886-3p has been reported 
to negatively regulate the proliferation, migration, and inva-
sion of NCI-H446 cells in vitro, as well as tumor growth, 
bone/muscle invasion, and lung metastasis in vivo, by repress-
ing the expression of its targets: PLK1 and TGF-β1, two well-
known active oncogenic genes.
The antitumor activity of miR-335 in SCLC has also 
been characterized. Human SCLC cells SBC-5 cells local-
ize to skeletal and nonskeletal sites, whereas SBC-3 cells 
only invade nonskeletal sites. The expression of miR-335 is 
reduced in SBC-5 compared with SBC-3 cells. In contrast, the 
expression of RANKL and IGF-1R, two key cytokines, are 
elevated in SBC-5 as compared with SBC-3 cells. Lentiviral 
overexpression of miR-335 in SBC-5 cells not only signifi-
cantly reduces in vitro carcinogenesis, cell migration, and 
invasion but also inhibits osteolytic lesions formation in vivo, 
which is mediated by upregulation of the IGF-1R and RANKL 
pathways.37
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Taken together, the above miRNAs have been indicated 
to function as tumor suppressors or oncogenes in SCLC and 
in many other cancer types. There are other miRNAs that have 
been characterized to promote or inhibit tumorigenesis in a 
variety of tumors including NSCLC, but whose functions have 
not been studied in SCLC. Therefore, there are more miRNAs 
with significance, which are worth evaluation in the context of 
SCLC. Moreover, among the above miRNAs, some have been 
only studied in cancer cells and consequently require further 
validation in tumor specimens and SCLC patients.
Clinical Application of miRNAs to the 
Diagnosis, Prognosis, and Therapy of sCLC
miRNAs as Diagnostic Biomarkers of SCLC
Because of the aggressiveness of SCLC, timely diag-
nosis is expected to improve the prognosis of SCLC patients. 
Unfortunately, no specific biomarker currently identifies early 
stage SCLC. Recently, several studies reported that a specific 
miRNA profile may serve as a reliable, noninvasive diagnostic 
tool for SCLC (see Table 2).
In an effort to investigate the contributions of miRNAs 
to the pathogenesis of SCLC and the possible use of miRNAs 
for its diagnosis, Du et al. performed microarray analysis to 
compare 136 miRNAs in a set of SCLC cell lines to that in 
a group of NSCLC cell lines and the normal immortalized 
HBEC line. They found that the miRNA profiles consistently 
distinguished the SCLC cell lines from NSCLC and HBEC 
cell lines, suggesting that the miRNA profile may serve as 
a diagnostic marker of SCLC.45 Gilad et al. developed an 
miR-based assay using pathologic and cytologic samples to 
differentiate between the four primary types of lung cancers: 
SCLC, cacinoid, and squamous and nonsquamous NSCLC. 
This assay included eight miRNAs (miR-106a, miR-125a-5p, 
miR-129-3p, miR-205, miR-21, miR-29b, miR-375, and miR-
7) and displayed an overall accuracy of 94% in the valida-
tion cohort.46 More recently, Huang et al.47 confirmed the high 
diagnostic accuracy of miR-205 to distinguish SQ from AC 
and SCLC in Chinese patients.
Apart from surgical and needle biopsy specimens, miR-
NAs can also be detected in bronchial brushing specimens. 
Two miRNA panels are constructed and validated, which 
distinguish SCLC from NSCLC and SQ from AC using not 
only FFPE surgical lung specimens but also bronchial brush-
ing specimens, indicating that these panels have considerable 
clinical value for differential diagnosis.48
Considering the high stability of miRNAs in body flu-
ids and in tissues, these molecules also represent potential 
biomarkers for the early, noninvasive detection of SCLC. 
According to published microarray data, Zheng et al. selected 
the 15 most frequently overexpressed miRNAs in lung can-
cer tissues and examined them in the plasma of lung cancer 
patients. They found that the levels of miR-155, miR-197, 
and miR-182 were significantly elevated compared with the 
controls, allowing for the discrimination between lung can-
cer patients and cancer-free controls with high specificity 
and sensitivity.49 This result demonstrates that only a subset 
of circulating miRNAs is likely derived from the secretion/
release of overexpressed miRNAs by tumor cells. Roth et 
al.50 provided evidence that a signature of miR-10b, miR-34a, 
miR-141, and miR-155 expression in serum discriminated 
lung cancer patients from healthy individuals. Although miR-
NAs are generally stable for several years, Keller et al. found 
that most obvious changes in the miRNA expression pattern 
appears to occur near the time of lung cancer diagnosis. This 
finding supports the concept that developing lung cancer 
might be detectable for years preceding traditional diagnosis 
based on a specific miRNA expression profile and that this 
profile changes during tumor development.51
miRNAs as Prognostic Biomarkers of SCLC
The prognosis always exerts a great effect on the selec-
tion of treatment. As a result, robust prognostic biomarkers 
are needed to improve clinical treatment selection. Growing 
evidence suggests that changes in miRNA expression can sig-
nificantly influence the prognosis of SCLC, which raises the 
possibility that miRNAs could serve as prognostic biomarkers 
in SCLC patients (see Table 3).
Ranade et al. suggested that a high level of miR-92a-2* 
expression is associated with a poor prognosis and shorter sur-
vival in SCLC patients. Moreover, stepwise multivariate analysis 
revealed that miR-92a-2* is an independent prognostic factor of 
SCLC.52 Bi et al. developed and validated that an miR-150/miR-
886-3P expression profile that significantly correlated to the 
overall survival (OS) of SCLC patients. And the risk score for 
each SCLC patient was calculated according to the expressions 
of miR-150 and miR-886-3p. Patients with high-risk miRNA 
expression profile experienced poor OS and progression-free 
survival compared with those with low-risk expression profiles, 
suggesting that this miRNA profile may represent an indepen-
dent predictor of survival.53 However, negative results have also 
been found. Lee et al.43 investigated the expression of a panel of 
seven miRNAs in SCLC tumors and found that these miRNAs 
are unrelated to the clinical characteristics of SCLC patients and 
are neither prognostic of OS or progression-free survival nor 
predictive of the response of these patients to treatment.
In addition to polymorphisms in miRNAs themselves, 
a growing number of miRNA-related polymorphisms have 
been demonstrated to be associated with the prognosis of 
SCLC. On the basis of multivariate analysis, Ding et al.54 
found that a polymorphism (rs16917496) in the miR-502 
binding site of the 3′ UTR of the SET8 gene is associated 
with SCLC patient survival. Similar phenomena were also 
detected for miR-1827 and miR-629. An SNP in an miRNA-
1827 binding site of MYCL1 results in the altered regulation 
of MYCL1 expression and may increase the susceptibility of 
these individuals to SCLC.55 In southern and eastern Chinese 
populations, a tagSNP in the miR-629 binding site of the 
NBS1 3′UTR confers an increased risk of lung cancer by 
diminishing the expression of this gene.56 It is proposed that 
SNPs located in the miRNA seed region of the 3′UTR of 
target genes might affect miRNA-mediated gene regulation 
and are thus associated with cancer susceptibility.57 Besides 
miRNA seed regions, SNPs in genes that encode the miRNA 
processing machinery as well as in pre-miRNAs, also affect 
cancer risk and patient prognosis. For example, Guo et 
al.58 reported that an miR-SNP located in the 3′UTR of the 
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miRNA processing gene xpo5 is associated with the OS of 
SCLC patients. They also found that the AA genotype cor-
relates to improved survival duration. Moreover, functional 
polymorphisms in pre-miR-146a and pre-miR-196a2 are 
associated with increased risk of lung cancer in Korea and 
Chinese individuals, respectively.26,27
miRNAs as Therapeutic Biomarkers of SCLC
Chemotherapy and radiotherapy are currently consid-
ered as the optimal treatment options for SCLC patients. 
However, drug and radiotherapy resistance have caused 
great clinical challenges. Therefore, identifying the molec-
ular mechanisms that regulate drug resistance responses is 
TABLE 2.  miRNAs as Diagnostic Biomarkers of SCLC
Experimental Setting Material Candidate miRNA Diagnostic Value Ref.
miRNA microarray analysis of 136 miRNAs in nine 
SCLC cell lines, seven NSCLC cell lines, and three 
HBEC lines
Cell lines miRNA panel 1: 30 
miRNAs including 
miR-101, miR-1, etc.
miRNA panel 2: miR-
31 and miR-205. 
miRNA panel 3: 29 
miRNAs including 
miR-16, miR-21, etc.
All miRNAs of miRNA panel 1 
are significantly differentially 
expressed between the SCLC and 
HBEC cell lines; two miRNAs of 
miRNA panel 2 are significantly 
differentially expressed between 
the NSCLC and HBEC cell lines; 
all miRNAs of miRNA panel 3 
are significantly differentially 
expressed between the SCLC and 
NSCLC cell lines.
45
Discovery: Microarray and PCR analyses of 94 primary 
resection samples from four histologic types of lung 
cancer (SCLC, SQ, nonsquamous NSCLC, and 
carcinoid). Training: Eight miRNAs were selected to 
be tested in 216 resection, biopsy, and FNA samples.
validation: Assessing the levels of these eight miRNAs 
in 451 resection, biopsy, FNA, and bronchial brushing 
and washing samples.
Pathologic and 
cytologic samples
miRNA panel: miR- 
106a, miR-125a-5p, 
miR-129-3p, miR-205, 
miR-21, miR-29b, miR-
375, and miR-7
The miRNA panel displays an 
overall accuracy of 93.7% 
and a sensitivity of >90% for 
classification of the four main 
types of lung cancer (SCLC, 
SQ, nonsquamous NSCLC, and 
carcinoid).
46
Discovery: qRT-PCR analysis of miR-205 expression in 
197 macrodissected surgical lung tissues.validation: 
The expression profiles of miR-205 were assessed in an 
independent cohort of 44 snap-frozen surgical lung tissues
Macrodissected 
surgical lung tissues 
and snap-frozen 
surgical lung tissues
miR-205 miR-205 discriminates SQ from AC 
and SCLC with an AUC of 0.985 
and 0.978, respectively.
47
Discovery: Microarray analyses of 723 miRNAs in 82 
snap-frozen surgical lung specimens.Training: qRT-PCR 
was performed on a training cohort of 85 macrodissected 
FFPE surgical lung specimens to evaluate seven miRNA 
candidates based on the microarrays analyses and to 
establish two miRNA panels.validation: Evaluation 
of the two miRNA panels in an independent cohort 
of 68 FFPE surgical lung specimens.Application: The 
effectiveness of the miRNA panels as differentiators of 
207 bronchial brushing specimens.
Snap-frozen surgical 
lung specimens, 
macrodissected 
FFPE surgical lung 
specimens, and 
bronchial brushing 
specimens
miRNA panel 1: miR-29a 
and miR-375; miRNA 
panel 2: miR-205 and 
miR-34a.
miRNA panel 1 discriminates SCLC 
from NSCLC with an AUC of 
0.947 (Sp 94%, Sn 79%); miRNA 
panel 2 discriminates SQ from AC 
with an AUC of 0.962 (Sp 88%, 
Sn 92%).
48
Analysis of 15 miRNAs frequently upregulated in lung 
cancer tissues from the plasma of 74 lung cancer patients 
(23 SQ, 18 AC, 17 SCLC, 7 large cell carcinoma, and 9 
others) and 68 age-matched cancer-free controls.
Total plasma RNA MiRNA panel: miR-155, 
miR-197 and miR-182
The miRNA panel displays 81.33% 
sensitivity and 86.76% specificity 
for discriminating the lung cancer 
patients from the controls.
49
Measurement of the concentrations of four circulating 
miRNAs in 35 lung cancer patients (19 NSCLC, 8 
SCLC, and 8 indefinite type), 7 patients with benign 
lung tumors, and 28 healthy individuals
Total cell-free RNA in 
blood serum
miR-10b, miR-34a, miR- 
141, and miR-155
The median expression levels of 
miR-10b, miR-34a, miR-141, and 
miR-155 are significantly higher in 
lung cancer patients than in healthy 
individuals, and the AUC values 
exceed 0.899 for each miRNA in 
distinguishing between lung cancer 
patients and healthy individuals; the 
levels of miR-10b, miR-141, and 
miR-155 are significantly higher in 
lung cancer patients than in patients 
with benign lung tumor, and the 
AUC values exceed 0.963 for each 
miRNA in distinguishing between 
lung cancer patients and patients 
with benign lung tumor.
50
AC, adenocarcinoma; AUC, area under the curve; CI, confidence interval; FFPE, formalin-fixed paraffin-embedded; FNA, fine-needle aspiration; HBEC, human bronchial 
epithelial cell; miRNAs, micro RNAs; NSCLC, non-small cell lung carcinoma; SCLC, small-cell lung carcinoma; Sn, Sensitivity; Sp, Specificity; SQ, squamous cell carcinoma; qRT-
PCR, quantitative real-time reverse transcription-polymerase chain reaction.
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TABLE 3.  microRNAs and miRNA-Related Polymorphisms as Prognostic Biomarkers of SCLC
Experimental Setting Material Candidate miRNA Prognostic Value Ref.
miRNA polymorphisms
Discovery: miRNA profiling of 34 diagnostic SCLC tumor samples 
analyzed using XenoBasevalidation: Assessing the top 16 miRNAs 
in 25 samples from the 34 SCLC tumor samples by qRT-PCR and 
their correlation to clinicopathological characteristics, normalized to 
5S-rRNA and RNU6
FFPE specimens miR-92a-a* High miR-92a-a* expression 
correlates with decreased 
median survival.
52
Discovery: Survey of the expression of 924 miRNAs from 42 SCLC 
patients through miRNA profiling to develop prognostic models. 
validation: assessing these models in an independent cohort of 40 
FFPE specimens through qRT-PCR
FFPE specimens The miR-150/ 
miR-886-3p 
profile
High expression levels of the 
miRNA profile correlates 
with poor OS and PFS.
53
Investigating the expression of a panel of 7 miRNAs in 31 SCLC tumors, 
14 SCLC cell lines, and 26 NSCLC cell lines and their correlation to 
clinical characteristics and sensitivity to cisplatin or etoposide.
FFPE specimens and 
cell lines
miRNA panel:  
miR-21, miR-29b, 
miR-34a/b/c,  
miR-155, and 
let-7a
The expression of the miRNA 
panel is neither prognostic 
of OS or PFS nor predictive 
of the response of the 
patients to treatment.
43
miRNA-related polymorphisms
Analyzing an SNP (rs16917496) within the miR-502 miRNA seed 
region in the 3′ UTR of SET8 in blood samples from 44 SCLC 
patients and 44 healthy female controls and correlation of this SNP 
to clinicopathological characteristics.
Blood samples The rs16917496 
polymorphism 
within the miR-502 
seed region of the 
3′ UTR of SET8
The SET8 CC + CT genotype 
is independently associated 
with longer survival.
54
Discovery: Identification of 26 genes that are markedly deregulated in 
SCLC using Web-based NextBio software, detection of 53 putative 
SNPs located in the 3′ UTR of these 26 genes that might generate 
or destroy miRNA-binding sites using Patrocles database and 
selection of two SNPs (rs3134615 G > T in the 3′UTR of MYCL1 
and rs2291854 C > T in the 3′UTR of ASCL1) displaying a MAF 
of 5% or greater from the putative SNPs.validation: analysis of the 
genotype distributions of these two SNPs and their association with 
SCLC susceptibility in 666 SCLC patients and 758 controls.
Peripheral blood 
samples
rs3134615 G > T 
located within the 
miR-1827 seed 
region of the 3′ 
UTR of MYCL1 
and rs2291854 C 
> T located in the 
3′UTR of ASCL1
The rs3134615T allele 
is associated with a 
significantly increased 
risk of SCLC compared 
with the GG genotype. 
No significant differences 
are detected in the risk of 
SCLC among the rs2291854 
genotypes.
55
Discovery: Identification of seven SNPs displaying a MAF of >5% in 
the 3′UTR of the NBS1 gene using the dbSNP database, analysis of 
the haplotype block based on the Chinese Han Beijing population data 
of HapMap, and selection of three haplotype-tagged SNPs (rs14448, 
rs13312986 and rs2735383) that might cover the genetic information of 
common SNPs in the 3′UTR of the NBS1 gene using Stram’s tagSNPs 
program.validation: Genotyping three tagSNPs (rs14448, rs13312986 
and rs2735383) in southern Chinese individuals (1056 SCLC cases and 
1056 controls) and then validating the discovered association in eastern 
Chinese individuals (503 SCLC cases and 623 controls).
Peripheral blood 
samples, lung 
cancer tissues 
and their adjacent 
normal tissues
Three tagSNPs 
(rs14448, 
rs13312986 and 
rs2735383) within 
the miR-629 
seed region of 
the 3′UTR of the 
NBS1 gene
The rs2735383CC genotype 
is associated with a 
significantly increased risk 
of lung cancer compared 
with the GG or GC 
genotype.
56
Analysis of an miRNA-related SNP (rs11077) in the 3′ UTR of XPO5 
in blood samples from 42 SCLC patients and its correlation to cancer 
survival.
Blood samples The rs11077 
polymorphism 
in the 3′ UTR 
of the miRNA 
processing 
machinery gene 
XPO5
The rs11077 AA genotype is 
significantly associated with 
longer survival time and 
better OS compared with 
the AC and CC genotypes.
58
Examination of the rs2910164 C > G genotypes in 1094 lung cancer 
patients and 1100 healthy controls and their association with lung 
cancer susceptibility.
Peripheral blood 
samples, cancer 
tissues and paired 
non-malignant 
lung tissues
rs2910164 C > G in 
pre-miR-146a
The rs2910164 CG or GG 
genotype is associated with 
a significantly decreased 
risk for lung cancer 
compared with the CC 
genotype in never smokers.
27
Discovery: Identification of 273 common genetic variants (MAF > 5%) 
in pre-miRNAs and their surrounding regions in all ethnic groups 
using the dbSNP database and selection of four pre-miRNA SNPs 
(rs2910164 C/G, rs2292832 C/T, rs11614913 T/C, and rs3746444 
A/G) located in the pre-miRNA regions.validation: evaluation of 
the associations between these four SNPs in pre-miRNAs and lung 
cancer susceptibility in a case-control study of 1058 incident lung 
cancer patients and 1035 cancer-free controls.
Blood samples rs11614913 T/C in 
pre-miR-196a2
The rs11614913 CC genotype 
is associated with a 
significantly increased risk 
of lung cancer compared 
with the TT and TC 
genotypes.
26
CI, confidence interval; FFPE, formalin-fixed paraffin-embedded; MAF, minor allele frequency; miRNAs, micro RNAs; OR, odds ratio; OS, overall survival; PFS, progression-free 
survival; SNP, single nucleotide polymorphism; qRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction.
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crucial for developing effective approaches to overcome 
such resistance and further improve patient prognosis. As 
reviewed here, our group and others have found that several 
miRNAs are closely associated with the response of patients 
to therapy and that some of these miRNAs are implicated 
in regulating chemosensitivity and radiosensitivity in SCLC 
(see Table 4).
Previously, we reported that overexpression of miR-
134, miR-379, and miR-495 increased the sensitivity of drug-
resistant H69AR SCLC cells to multiple drugs, including 
doxorubicin, cisplatin, and etoposide, whereas knockdown of 
these miRNAs decreased this sensitivity. Further investiga-
tion revealed that miR-134 increases drug sensitivity in part 
through downregulation of MRP1/ABCC1, which contributes 
to chemoresistance and decreased cell survival by attenuat-
ing G1 phase arrest in H69AR cells.58 Recently, we found 
that another miRNA, miR-100, modulates chemosensitiv-
ity in H69 and H69AR cells by directly targeting HOXA1.59 
Furthermore, Li et al.60 demonstrated that miR-137 is closely 
associated with SCLC multidrug resistance, and that interfer-
ing with miR-137 expression may decrease cisplatin resis-
tance in drug-resistant H446/CDDP SCLC cells partly by the 
regulation of KIT expression.
Other miRNAs are also associated with drug resistance 
in SCLC, although the mechanisms remain unclear. MiRNA 
microarray analysis revealed that miR-92a-2*, miR-147, and 
miR-574-5p are significantly associated with chemoresistance 
in SCLC tumor samples.52 However, not all miRNAs affect 
response to chemotherapy. Lee et al.43 found that the expres-
sion of a panel of seven miRNAs predicts neither the treat-
ment response of SCLC patients nor the sensitivity of SCLC 
cell lines cisplatin or etoposide in vitro.
In addition to chemosensitivity, miRNAs are also 
related to radiotherapy responses. MiRNA microarray analy-
sis showed higher expression of miR-324-5p in SCLC radio-
resistant cells than in radiosensitive cells, which was validated 
by qRT-PCR analysis.61 In addition, the effect of core miRNA 
biogenesis machinery proteins on the response of lung cancer 
cell lines to treatment with ionizing radiation was assessed. 
Neither knockdown of these core proteins involved in miRNA 
biogenesis nor downregulation of the primary components of 
the RISC sensitized these cells to irradiation.62
Recent studies have shown that miRNA signature is a 
rising star that may provide new resolutions for SCLC. miR-
NAs are much more stable in blood and tissues, raising the 
exciting prospect that miRNAs might be used as diagnostic, 
prognostic, and therapeutic biomarkers for SCLC.
LNCRNAs iN sCLC
LncRNAs, a heterogeneous group of ncRNAs that are 
more than 200 nt in length, comprise the largest portion of the 
mammalian noncoding transcriptome.6 LncRNAs are known 
to mediate epigenetic modifications of DNA by recruiting 
chromatin-remodeling complexes to specific loci in either 
the nucleus or the cytoplasm. However, the signals that drive 
their localization have yet to be established.6,63–65 The involve-
ment of lncRNA in SCLC is not as well understood as that 
of miRNA. To date, only one study has reported a role of 
lncRNA in SCLC, and the specific alteration of the lncRNA 
was not elucidated. However, lncRNA has become an impor-
tant topic of research, and its functional role in SCLC cannot 
be discounted.
Hox transcript antisense intergenic RNA (HOTAIR) is 
one of the few well-studied lncRNAs. HOTAIR is transcribed 
from the HoxC gene and binds as a scaffold to polycomb 
repressive complex 2 (PRC2) and the LSD1-CoREST-REST 
complex, leading to the catalysis of H3K27 trimethylation 
and the spontaneous demethylation of H3K4, as well as to 
the repression of HoxD genes transcription.66,67 Ono et al. 
assessed HOTAIR expression in SCLC cell lines and surgi-
cal SCLC samples through qRT-PCR analysis. They found 
that HOTAIR is more strongly expressed in SCLC cell lines 
and tumor tissues than in normal cells and tissues. Knocking 
down HOTAIR in SBC-3 SCLC cells inhibits their prolifera-
tive activity and invasiveness in vitro. Moreover, high expres-
sion of HOTAIR is associated with an aggressive phenotype 
and poor prognosis, suggesting that HOTAIR could be used as 
a prognostic biomarker.34
TABLE 4.  miRNAs and miRNA-Related Molecules as Therapeutic Biomarkers of SCLC
miRNA Material Main Finding Mediator Ref.
miR-134, miR-379, and miR-495 A SCLC cell line and its  
drug-resistant subline
Increase sensitivity to adriamycin, 
cisplatin and etoposide
miR-134 downregulates 
MRP1/ABCC1
58
miR-100 A SCLC cell line and its  
drug-resistant subline
Induces resistance to adriamycin, 
cisplatin and etoposide
Directly targets HOXA1 59
miR-137 A SCLC cell line and its  
drug-resistant subline
Sensitizes SCLC cells to cisplatin Downregulates KIT 60
miR-92a-2*, miR-147, and  
miR-574-5p
FFPE samples Positively correlates with 
chemoresistance
NS 52
miRNA panel: miR-21, miR-29b, 
miR-34a/b/c, miR-155, and let-7a
FFPE tumor samples and 
cell lines
No effect on the sensitivity to 
cisplatin or etoposide
NS 43
miR-324-5p SCLC cell lines upregulated in SCLC radio- 
resistant cells
NS 61
Core proteins involved in miRNA 
biogenesis
SCLC cell lines No effect on the sensitivity to 
ionizing irradiation
NS 62
FFPE, formalin-fixed paraffin-embedded; miRNAs, micro RNAs; NS, not specified; SCLC, small-cell lung carcinoma.
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CELL-FREE RNA iN sCLC
As recently as 10 years ago, Schmidt et al. investigated 
whether cell-free RNA could be detected in the supernatant 
of bronchial lavage fluid (BLF) and in serum. They success-
fully isolated and quantified cell-free RNA from serum and 
BLF supernatants of lung cancer patients, as well as patients 
with a benign lung disease. Furthermore, the cell-free RNA 
levels were higher in the BLF supernatant than in serum, 
and the RNA concentration in BLF from tumor patients was 
higher than in that from non-tumor patients, suggesting that 
the quantification of cell-free RNA levels in BLF supernatants 
and serum may represent a new diagnostic tool to differentiate 
between lung cancer patients and patients without tumors.68
DisCUssiON
To date, a considerable number of studies have inves-
tigated the roles of ncRNAs in lung cancer. However, most 
of these studies have focused on NSCLC, whereas far fewer 
studies of SCLC, the most lethal lung cancer subtype. 
Because the same ncRNAs might be expressed in differ-
ent lung cancer subtypes but perform distinct functions, the 
results of studies of NSCLC or other subtypes cannot neces-
sarily be applied to SCLC. For example, miR-34a, which is 
activated by P53, plays a pivotal role in regulating NSCLC 
cell survival. However, in SCLC, neither upregulation nor 
downregulation of miR-34a influence cell viability or drug 
sensitivity, and its activity is unrelated to P53 expression.39 
Therefore, it is imperative to devote more effort to the study 
of ncRNAs in the context of SCLC. Furthermore, the iden-
tification of ncRNAs that specifically regulate cell survival 
and drug responses in SCLC may facilitate the development 
of specific therapeutic regimens.
Among the ncRNAs implicated in SCLC (Fig. 1), miR-
NAs are the most extensively studied. Cytological evidence 
indicates that numerous miRNAs are involved in tumori-
genesis and function as oncogenes or tumor suppressors in 
SCLC. Several miRNAs have been identified as diagnostic 
or prognostic biomarkers of SCLC with high sensitivity and 
specificity. However, there remains a lack of clinical stud-
ies identifying the miRNAs that are altered during the early 
phases of carcinogenesis. Such studies will be critical for 
making early diagnoses and improving the management of 
SCLC. Although previous studies reported that cancer-related 
miRNAs can be detected in serum before clinical diagnosis, 
the prediagnostic circulating miRNA expression profiles have 
yet to be elucidated for SCLC. This lack of understanding is 
partially due to the aggressiveness of SCLC and the difficulty 
in collecting sufficient and appropriate samples to study this 
disease during its initial stages.
FiGURE 1.  Structure of noncoding 
RNAs in small-cell lung cancer.
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Besides, accumulating evidence suggests a role for miR-
NAs in regulating the response of a tumor to therapy, which 
may guide the design of personalized, novel therapeutic strate-
gies based on specific miRNA expression levels. However, it 
is necessary to consider the nonspecificity of miRNA targets, 
as well as effective and nontoxic delivery systems. The issues 
must be addressed before translating basic studies into clinical 
applications.
Currently, as miRNA expression profiling reaches a pla-
teau, lncRNA has opened an intriguing new area of study in 
cancer biology. Despite our currently limited understanding of 
the role of lncRNAs, increasing studies highlight the exciting 
prospect that these molecules may serve as new biomarkers of 
and therapeutic targets for human cancers.6,8 Significant effort 
is required to discover additional ncRNAs that perform cru-
cial biological functions and to determine the mechanisms and 
roles of these molecules in SCLC.
In conclusion, the studies of ncRNAs not only provide 
a new insight into SCLC biology but also broaden the library 
of valuable biomarkers that can be used for SCLC diagnosis, 
prognosis, and therapy. Clinical applications of ncRNAs for 
SCLC are expected in the future, although there remain major 
hurdles to overcome.
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